Form 10-Q INOVIO PHARMACEUTICALS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Inovio's (INO) DNA Technology Platform Further Validated with Latest Qtr. Results - Stifel
November 9, 2015 2:46 PM ESTStifel affirms its Buy rating and $19 price target on Inovio (Nasdaq: INO) following the company's Q3 report and update issued earlier Monday.
Analyst Thomas Shrader, PhD, CFA, noted that EPS of $0.07 was flat with consensus estimates and revenue was driven by... More
Inovio Pharma (INO) Swings to Q3 Profit
November 9, 2015 6:28 AM ESTInovio Pharma (NASDAQ: INO) reported Q3 EPS of $0.07, versus ($0.12) reported last year. Revenue for the quarter came in at $24.18 million, versus $1.84 million reported last year.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... More